Issue of Options

RNS Number : 7952X

Physiomics PLC

13 February 2013

 



Physiomics plc

(the "Company" or "Physiomics")

Issue of Options

 The Company confirms that it has agreed to issue share options to each of its directors, as follows:

12,938,121 share options over ordinary shares in the Company ("Share Options") have been granted to each of Mark Chadwick and Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 0.132p each (being the average mid-market closing price for the three days prior to the date of issue).

A total of 5,175,248 share options over ordinary shares in the Company ("Share Options") have now been granted to Paul Harper under an Unapproved share option scheme. The options are exercisable at a price of 0.132p each.

The options can be exercised within 10 years of the date of grant provided that satisfaction is achieved of certain pre-defined commercial conditions.

If all the new Share Options were to be exercised, they would represent 2.06% of the current issued share capital of the Company.

Following this issue, Mark Chadwick and Christophe Chassagnole will each hold 41,151,873 share options and Paul Harper will hold 16,460,749 share options over ordinary shares in the Company in accordance with the table below.

		Share Options
	Award no.	Granted	Exercise price	Expiry date
			p
Paul Harper	1	2,327,710	0.15	18-Dec-18
	2	7,664,541	0.40	28-Feb-20
	3	1,293,250	0.34	08-Nov-21
	4	5,175,248	0.132	11-Feb-23
Christophe Chassagnole	1	7,499,453	0.383	06-Sep-17
	2	5,624,590	0.15	18-Dec-18
	3	11,856,584	0.40	28-Feb-20
	4	3,233,125	0.34	08-Nov-21
	5	12,938,121	0.132	11-Feb-23
Mark Chadwick	1	19,984,500	0.27	05-Dec-20
	2	3,233,127	0.34	08-Nov-21
	3	4,996,125	0.293	18-Dec-21
	4	12,938,121	0.132	11-Feb 23

Enquiries:

Physiomics plc                                                  

Mark Chadwick 

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

 Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

 Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

MSCTJMBTMBMBBRJ